Peroxisomal ABC transporters: Structure, function and role in disease  by Morita, Masashi & Imanaka, Tsuneo
Biochimica et Biophysica Acta 1822 (2012) 1387–1396
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReview
Peroxisomal ABC transporters: Structure, function and role in disease☆
Masashi Morita, Tsuneo Imanaka ⁎
Department of Biological Chemistry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, JapanAbbreviations: ABCD, ATP-binding cassette protein s
loneuropathy; CCALD, child cerebral ALD; CNS, central
droxycholestanoic acid; DHA, docosahexaenoic acid; G
iPS, induced pluripotent stem; NBD, nucleotide-binding
polymorphism; THCA, trihydroxycholestanoic acid; T
PUFA, polyunsaturated fatty acid; ROS, reactive oxyg
chain fatty acids; X-ALD, X-linked adrenoleukodystroph
☆ This article is part of a Special Issue entitled: Metabo
Peroxisomes in Health and Disease.
⁎ Corresponding author. Tel.: +81 76 434 7545; fax:
E-mail address: imanaka@pha.u-toyama.ac.jp (T. Im
0925-4439/$ – see front matter © 2012 Elsevier B.V. All
doi:10.1016/j.bbadis.2012.02.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 October 2011
Received in revised form 7 January 2012
Accepted 8 February 2012
Available online 17 February 2012
Keywords:
ABC transporter
Acyl-CoA transport
Adrenoleukodystrophy
Fatty acid β-oxidation
Peroxisome targetingATP-binding cassette (ABC) transporters belong to one of the largest families of membrane proteins, and are pre-
sent in almost all living organisms fromeubacteria tomammals. They exist on plasmamembranes and intracellular
compartments such as the mitochondria, peroxisomes, endoplasmic reticulum, Golgi apparatus and lysosomes,
and mediate the active transport of a wide variety of substrates in a variety of different cellular processes. These
include the transport of amino acids, polysaccharides, peptides, lipids and xenobiotics, including drugs and toxins.
Three ABC transporters belonging to subfamily D have been identiﬁed inmammalian peroxisomes. The ABC trans-
porters are half-size and assemble mostly as a homodimer after posttranslational transport to peroxisomal mem-
branes. ABCD1/ALDP and ABCD2/ALDRP are suggested to be involved in the transport of very long chain acyl-CoA
with differences in substrate speciﬁcity, and ABCD3/PMP70 is involved in the transport of long and branched chain
acyl-CoA. ABCD1 is known to be responsible for X-linked adrenoleukodystrophy (X-ALD), an inborn error of per-
oxisomal β-oxidation of very long chain fatty acids. Here, we summarize recent advances and important points in
our advancing understanding of how these ABC transporters target and assemble to peroxisomal membranes and
perform their functions in physiological and pathological processes, including the neurodegenerative disease, X-
ALD. This article is part of a Special Issue entitled: Metabolic Functions and Biogenesis of Peroxisomes in Health
and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Peroxisomes are organelles bounded by a single membrane that
are present in almost all eukaryotic cells. These organelles are in-
volved in a variety of metabolic processes, including the β-oxidation
of fatty acids, especially very long chain fatty acids (VLCFA), and the
synthesis of ether phospholipids and bile acids in mammals [1–3].
These metabolic pathways require the transport of metabolites in
and out of peroxisomes [4]. Recently it has become clear that the
transport of such metabolites is facilitated by at least a few different
metabolic transporters. One of the transporter families is the ATP-
binding cassette (ABC) transporter.
The ABC transporters comprise a superfamily of membrane-bound
proteins found in almost all organisms from eubacteria to mammals.
The structure of the ABC proteins is highly conserved, and theyubfamily D; AMN, adrenomye-
nervous system; DHCA, dihy-
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domain; SNP, single nucleotide
MD, transmembrane domain;
en species; VLCFA, very long
y
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anaka).
rights reserved.catalyze the ATP-dependent transmembrane transport of awide variety
of substrates. The ABC transporters are classiﬁed into two groups, ABC
importers and ABC exporters [5,6]. The ABC importers are limited to
prokaryotes and function as an uptake system for nutrients. The ABC ex-
porters mediate the cellular secretion of toxic compounds and various
kinds of lipids. Almost all eukaryotic ABC transporters function as ex-
porters and are localized to plasmamembranes aswell as the endoplas-
mic reticulum (ER), Golgi apparatus, lysosomes, peroxisomes and
mitochondria. They export various substrates into the extracellular
space, and also to the lumen of subcellular organelles or the inner mito-
chondrial space, which is considered to be an “extracellular space” in
eukaryotic cells. The humanABC transporter family currently comprises
49 members, if ABCC13, which lacks the ABC region, is included. They
are divided into seven subfamilies based on structural organization
and amino acid homology [7,8]. The human ABC proteins are involved
in a number of important physiological processes and dysfunction of
the ABC transporters is known to cause severe diseases such as Tangier
disease (ABCA1), harlequin ichthyosis (ABCA12), cystic ﬁbrosis
(ABCC7) and X-linked adrenoleukodystrophy (X-ALD) (ABCD1).
To date, three ABC proteins have been identiﬁed inmammalian per-
oxisomes and classiﬁed into “subfamily D”. These are adrenoleukodys-
trophy protein (ALDP/ABCD1), ALDP-related protein (ALDRP/ABCD2)
and a 70-kDa peroxisomal membrane protein (PMP70/ABCD3) [9–14].
Dysfunction of ABCD1 is the cause of the human genetic disorder X-
ALD, which is characterized by an accumulation of VLCFA because of
an impaired peroxisomal β-oxidation of VLCFA [9]. These patients
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adrenal insufﬁciency and testicular dysfunction. ABCD2 is suggested to
be involved in the metabolic transport of VLCFA, since ABCD2 has a
high sequence similarity to ABCD1, and the expression of ABCD2 re-
stored VLCFA β-oxidation in X-ALD patient ﬁbroblasts [15]. ABCD3 is
suggested to be involved in the metabolic transport of long chain fatty
acids, since the overexpression of ABCD3 in CHO cells induced the β-
oxidation of palmitic acid [16]. In addition, Abcd3(−/−) knockout
mice exhibit abnormalities in peroxisomal metabolism of the bile acid
intermediates pristanic acid and phytanic acid (Jimenez-Sanchez G et
al. Am J Hum Genet 2000, meeting abstract Nr 282), suggesting that
ABCD3 is also involved in the transport of bile acid intermediates and
branched chain fatty acids. PMP70-related protein (P70R/ABCD4) is
also a member of the ABC protein subfamily D [17,18]. Recently, we
reported thatABCD4 is localized to ER, not to peroxisomes, but the func-
tion of ABCD4 still remains unknown [19].
In this review, we will focus on recent advances in the understanding
of howperoxisomal ABC transporters target and assemble to peroxisomalCNH2
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Fig. 1. Hypothesized structure of the peroxisomal ABC half-transporter (a) and the possible
half-size ABC transporter with one transmembrane domain (TMD) and one nucleotide-bind
the transporter, and Walker A, B and ATP-binding Cassette signature sequence (the ABC sign
proteins (ABCD1, ABCD2 and ABCD3) belonging to subfamily D are known to exist in perox
substrate speciﬁcities toward saturated and monounsaturated VLCFA-CoAs. However, ABCD1
higher speciﬁcity for C22:0-CoA and C20:0-CoA than ABCD1. ABCD2, but not ABCD1, has an
port of LCFA-CoA, branched chain acyl-CoA, THCA-CoA and DHCA-CoA.membranes and perform their functions in both physiological and patho-
logical processes. A very recent review about peroxisomal ABC trans-
porters is also helpful in understanding the ABC transporters in health
and disease [20].2. Structure of peroxisomal ABC transporters
Peroxisomal ABC transporters have a predicted structure of an
ABC half-transporter with one transmembrane domain (TMD) and
one nucleotide-binding domain (NBD). The hydropathy proﬁle of
the human peroxisomal ABC transporters predicts that the amino ter-
minal half of the peroxisomal ABC transporters is hydrophobic, with
six transmembrane segments, and the COOH-terminal half is hydro-
philic, having NBD (Fig. 1) [21]. TMD provides the passageway for
the substrate across the membranes and NBD energizes the direction-
al transport of these substrates by cycles of ATP binding and hydroly-
sis. NBD contains two conserved motifs: Walker A and Walker B,OOH
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Cytosol
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ADP
ABCD1
ABCD2
ABCD3
-Oxidation
function of ABC transporters on peroxisomal membranes (b). ABCD transporters are a
ing domain (NBD). Six transmembrane domains are located in the NH2-terminal half of
ature) are located in the COOH-terminal half of the transporter. In mammals, three ABC
isomes, and predominately exist as a homodimer. ABCD1 and ABCD2 have overlapping
has higher speciﬁcity to C24:0-CoA and C26:0-CoA than ABCD2. In contrast, ABCD2 has
afﬁnity for polyunsaturated VLCFA-CoA. ABCD3 is thought to be involved in the trans-
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motif is situated upstream of the Walker B sequence [5,7].
Protease treatment of peroxisomes indicated that the NBD of
ABCD1 and ABCD3 are exposed to the cytosol [14,21]. In terms of
the ATP-binding and hydrolysis activities of ABCD1, Roerig et al.
reported that the recombinant NBD of ABCD1 bound and hydrolyzed
ATP [22]. Tanaka et al. also detected the ATP binding and hydrolysis
activities of native ABCD1 and ABCD3 in rat liver peroxisomes by
photoafﬁnity labeling with 8-azido-[α-32P]ATP and 8-azido-[γ-32P]
ATP [23]. Using limited-trypsin digestion, we investigated the effect
of ATP-binding and hydrolysis on the conformation of ABCD3. The
binding and hydrolysis of ATP were found to induce conformational
changes in ABCD3 close to the boundary between the transmembrane
and NBD, and the helical domain betweenWalker A and Bmotifs [24].
On the other hand, the TMD of ABCD1 is proposed to be involved in
substrate-recognition and to form a transport pathway across the
peroxisomal membrane. Guimaraes et al. assessed the substrate-
induced conformational alterations in ABCD1 with a protease-based
assay, and found that long- and very long chain acyl-CoA increased
the sensitivity of the NH2-terminal 44-kDa fragment of ABCD1 to Factor
Xa, and this acyl-CoA induced sensitivity was reversed by the presence
of ATP-γS [25]. These ﬁndings suggest that the NH2-terminal TMD of
ABCD1 is involved in the recognition of these substrates, and undergoes
a conformational change upon ATP binding to the COOH-terminal NBD
of ABCD1 and ABCD3.
As most of the half-size ABC proteins identiﬁed to date dimerize in
order to form a functional transporter, it has been suggested that the
peroxisomal ABC proteins also need to assemble as homo- or hetero-
dimers on the peroxisomal membranes to form a functional unit. In
terms of the quaternary structures of peroxisomal ABC proteins, Liu
et al. were the ﬁrst to show the occurrence of homo- as well as hetero-
dimeric interactions among ABCD1, ABCD2 and ABCD3 by using a yeast
two-hybrid system and co-immunoprecipitation experiments [26]. We
also showed by means of co-immunoprecipitation studies that ABCD1
forms a stable complex with ABCD3 and certain peroxisomal proteins
on rat liver peroxisomal membranes [23]. On the other hand, Guimaraes
et al. reported that mouse liver ABCD1 and ABCD3 are a mostly homo-
meric protein structure, based on sucrose density gradient analysis and
immunoprecipitation experiments with digitonin-solubilized mouse
liver peroxisomes [27]. Furthermore, FRET microscopy experiments inLignoceroyl-CoA
ATP
Peroxisomal membrane
Peroxisomal matrix
Fig. 2. A hypotheticalmodel of substrate transport by the peroxisomal ABC transporter. Substra
cytosol and/or leaﬂet of the lipid bilayer facing cytosol. ATP binds to the NBD, causing a large c
peroxisome and/or the leaﬂet facing lumen of peroxisome. Thismodel is drawnup on the base o
conformation of lignoceroyl-CoA in aqueous solution is also made up based on energy minimi
software, CCP4mg was used to generate this model [113].intact living cells demonstrated that ABCD1 and ABCD3 form a homodi-
mer, although ABCD1 can also form a heterodimer with ABCD3 [28].
These data suggest that ABCD1 and ABCD3mainly are found as a homo-
dimer in mammalian peroxisomal membranes, although ABCD1 can
form a complex with ABCD2 or ABCD3.
Currently, one of the key outstanding questions is how peroxisomal
ABC transporters recognize their substrates and import them into the
lumen of peroxisomes. Although the X-ray crystallographic structure
of peroxisomal ABC transporters has not yet obtained, recently the
mouse Abcb1 (Mdr1, P-glycoprotein) was reported at 3.8 Å resolution
[29]. The structure of Abcb1 represents a nucleotide-free inward-
facing conformation in the plane of the lipid bilayer. The inward facing
conformation results in a large internal cavity open to both the cyto-
plasm and the inner leaﬂet. The inward-facing conformation represents
an initial stage of the transport cycle that is suitable for drug binding.
The substrate enters the internal drug-binding pocket through an
open portal and the residues in the drug binding pocket interact with
the substrate. ATP binds to the NBD, causing a large conformational
change, thereby presenting the substrate and drug-binding site(s) to
the outer leaﬂet/extracellular space. Based on these ﬁndings and the
structure of bacterial multidrug ABC transporters Sav1866 [30] and
MsbA [31], peroxisomal ABC transporters might capture acyl-CoA de-
rivatives from cytosolic side and transport them to the lumen of perox-
isome through ATP binding and hydrolysis (Fig. 2). The arrangement of
TMDs that compose the cavity of acyl-CoA for the substrate, and the
linkage between the TMD and NBD, might have a conformation that is
different from other ABC transporters in order to transport acyl-CoA
derivatives.
3. Targeting of peroxisomal ABC transporters
Recent studies have demonstrated that peroxisomes originate
from ER as pre-mature peroxisomes and mature as the result of post-
translational transport of peroxisomal membrane and matrix pro-
teins. The peroxisomes then undergo growth and division [32–34].
According to certain very recent ﬁndings, the biogenesis of the perox-
isomal membranes is different in yeast and mammals. In yeast, it is
suggested that a set of peroxisomal membrane proteins such as
Pex3p, Pex13p, Pex14p and Pex15p is transported to the ER and
then bud as premature peroxisomes [35,36]. However, in mammalian90o
Cytosol
te (lignoceroyl-CoA) enters putative substrate-binding pocket of the ABC transporter from
onformational change of the ABC transporter. The substrate is released into the lumen of
f structures of p-gp, Sav1866 andMsbA deposited in Protein Data Bank [29–31]. A possible
zation calculation, and in lipid bilayer based on NMR study [112]. The molecular-graphics
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duced to become either premature or mature peroxisomes through
the steps of maturation and division.
At least two peroxin proteins, Pex3p and Pex19p, have central
functions in the generation of the peroxisome membrane structure
[37]. In the cycle of peroxisome formation, Pex3p and Pex19p play a
role in the insertion of newly synthesized peroxisomal membrane pro-
teins into preexisting peroxisomes (Fig. 3). Pex19p is a hydrophilic and
acidic protein which functions as both an acceptor and chaperone,
thereby preventing the aggregation and degradation of peroxisomal
membrane proteins [38,39]. We showed that the in vitro translation of
ABCD3 in the presence of puriﬁed Pex19p resulted in soluble ABCD3
that co-immunoprecipitated with Pex19p. However, in the absence of
Pex19p, ABCD3 formed aggregates during translation. Pex19p com-
plexedwith peroxisomalmembrane proteins associates with its docking
factor Pex3p on peroxisomal membranes, and peroxisomal membrane
proteins are unloaded on the membranes (Fig. 3) [40,41].
Concerning the trafﬁcking of the newly synthesized peroxisomal
ABC transporters, ABCD3 has been characterized in some detail
[39,42–44]. We investigated the targeting signal of ABCD3
(AA.1–659) to peroxisomes using various NH2-terminal or COOH-
terminal truncated ABCD3 fused to green ﬂuorescent protein (GFP)
[43]. The COOH-terminally truncated ABCD3 (AA.1–144)-GFP, com-
posed of TMD1 and TMD2 of ABCD3, and GFP-ABCD3 (AA.263–375),
composed of TMD5 and TMD6, were found to be localized to peroxi-
somes. Through further analysis of the targeting signal of ABCD3 by
site-directed mutagenesis, we suggest that ABCD3 is recognized and
binds to Pex19p at the NH2-terminal hydrophobic motif constituted
by Leu21-Leu22-Leu23 and the region of TMD5-TMD6. The ABCD3-
Pex19p complex is transported to peroxisomes by the peroxisomalmem-
brane protein targeting signals (mPTSs) located in the NH2-terminal 124-
amino acid region and the region of AA.263–375 (the hydrophobicity of
Ile70-Leu71 and Ile307-Leu308 might be essential). Finally, ABCD3 is
inserted into the peroxisomalmembranes through the putative proteina-
ceous components on the peroxisomal membranes. In this process, at
least two TMDs (TMD1 and TMD2) are required for proper insertion [43].
The targeting of ABCD1 to peroxisomes has also been characterized.
Rottensteiner et al. found a Pex19p binding site consisting of a 15-
amino-acid conserved consensus motif, which consists of a cluster ofperoxisome
ABCD
Pex19p
Pex3p
ABCD
Fig. 3. Targeting of the peroxisomal ABC transporter to the peroxisomal membrane.
The peroxisomal ABC transporter translated on free ribosomes is selectively captured
by Pex19p in the cytosol. The interaction becomes more stable by the TMDs located
downstream of the NH2-terminal Pex19p binding motif. As a result, the peroxisomal
ABC transporter keeps soluble and proper conformation in the cytosol. Then, the peroxisomal
ABC transporter-Pex19p complex binds to Pex3p through the interaction of theNH2-terminal
Pex3p binding motif of Pex19p, consisting of Leu18, Leu21, Leu22, Phe29, and Trp104 in the
α2-helix of Pex3p. Finally, the peroxisomal ABC transporter is inserted into the peroxisomal
membrane and Pex19p shuttles back to the cytosol to initiate another import cycle. However,
the mechanisms by which Pex19p unloads the ABC transporter and shuttles back have not
yet elucidated.basic and possibly hydrophobic amino acids: [F(F/L)X(R/Q/K)(L/F)(L/I/
K)XLLKIL(F/I/V)P] that has been identiﬁed in the amino-terminal close
to the ﬁrst TMD [45]. Deletion of the Pex19p binding site in ABCD1
(amino acid residues 71–84) abolished peroxisomal targeting. A similar
sequence exists at AA.59–73 and 82–96 of ABCD3, but the afﬁnity of
these regions was found to be very weak compared to that of ABCD1
[46]. Nonetheless, these sequences are located in the region adjacent
to the TMD1of ABCD1 and 3, andmay have an important role in the tar-
geting of the proteins to peroxisomes togetherwith TMD1and TMD2. In
ABCD2, a potential Pex19p binding site was also identiﬁed as ABCD1
[46]. It corresponds to AA.84–97, which are localized in the proximity
of the putative TMD1. Unfortunately, no experimental data are available
as yet to support the functionality of this putative Pex19p binding site.
ABCD4 is a member of the ABC transporter subfamily D. We dem-
onstrated in CHO cells that transiently expressed ABCD4 in fusion
with HA (ABCD4-HA) was localized to the ER, not peroxisomes and
endogenous ABCD4 in rat liver was detected in microsomal fraction
by subcellular fractionation [19]. These results suggest that ABCD4
might be located to the ER. The ABC subfamily D transporters des-
tined for peroxisomes have an NH2-terminal hydrophilic region that
binds to the Pex19p adjacent to TMD1, as mentioned above. However,
only ABCD4 lacks the region and is translatedwith only the NH2-terminal
hydrophobic TMD1. Therefore, it seems likely that the hydrophobicity of
the NH2-terminal region determines the subcellular localization of the
ABC subfamily D transporters.
4. Function and regulation of peroxisomal ABC transporters
4.1. ABCD1
X-ALD is caused by mutations in the ABCD1 gene that result in a
defect in the ABCD1 protein and the accumulation of VLCFA and/or
VLCFA-CoA. Therefore, it is thought that ABCD1 functions as a trans-
porter of VLCFA across the peroxisomal membrane. This is supported
by the result that transfection of ABCD1 cDNA into X-ALD skin ﬁbro-
blasts restored the VLCFA β-oxidation, and consequently, the VLCFA
content returned to normal in the ﬁbroblasts [47,48]. Recently, van
Roermund et al. have further demonstrated that ABCD1 is involved
in the transport of saturated, monounsaturated and polyunsaturated
VLCFA-CoA (such as C18:0-, C22:0-, C24:0-, C26:0-, C18:1- and
C24:6-CoA) across the peroxisomal membranes by expressing
human ABCD1 in a PXA1/PXA2 knockout yeast mutant [49,50]. In
fact, the level of C24:0-CoA and C26:0-CoA in X-ALD ﬁbroblasts was
reported to become elevated when X-ALD ﬁbroblasts were incubated
with C24:0 [51]. These ﬁndings strongly suggest that ABCD1 is in-
volved in the uptake of a wide range of VLCFA-CoA forms into
peroxisomes.
ABCD1 gene expression is reportedly affected by the cholesterol
level in human THP-1 cells and primary macrophages [52]. In
Abcd1-deﬁcient mice, the plasma cholesterol level was higher than
that in wild-type mice and was not increased by cholesterol-feeding
whereas the level in cholesterol-fed wild-type mice was increased
[53]. These ﬁndings suggest a link between ABCD1 function and cellu-
lar cholesterol metabolism. However, the mechanism by which cho-
lesterol affects Abcd1 gene expression has not yet been elucidated.
4.2. ABCD2
It is generally accepted that ABCD2 has a certain functional redun-
dancy with ABCD1 [54]. However, the differences in the expression
patterns and phenotypes of Abcd1-deﬁcient and Abcd2-deﬁcient
mice suggest that there are certain other speciﬁc roles for ABCD2 in
lipid metabolism. This is supported by the report that ABCD2 comple-
ments the germination phenotype of an Arabidopsis cts-1 mutant that
lacks the peroxisomal ABCD transporter CTS/AtABCD1, but ABCD1
does not [55].
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docosahexaenoic acid (DHA), was reduced in Abcd2-deﬁcient mice
brain. In addition, ABCD2 expression is highly sensitive to dietary
polyunsaturated fatty acids (PUFA), suggesting that Abcd2 is involved
in the transport of PUFA in relation to DHA metabolism [50,56,57].
This is supported by experiments using yeast expression system in
which ABCD1 and/or ABCD2 was expressed in a pxa1/pxa2 knockout
yeast mutant. van Roermund et al. have shown that ABCD2 has over-
lapping substrate speciﬁcities with ABCD1 toward saturated fatty
acids and monounsaturated fatty acids such as C24:0-CoA, C26:0-
CoA, C20:1-CoA and C22:1-CoA [50], although ABCD2 has a higher
speciﬁcity for C22:0-CoA and C20:0-CoA than ABCD1. In contrast,
ABCD2 has an afﬁnity for PUFA such as C22:6-CoA and C24:6-CoA,
but ABCD1 does not. These results are good agreement with the re-
sults from ABCD2-overexpressing H4IIEC3 cells [57].
It has been suggested that ABCD2 might be more important than
ABCD1 in the control of oxidative stress, because ABCD2 is involved
in the metabolism of monounsaturated VLCFAs (C26:1) which
might be related to oxidative damage to proteins [58]. These results
are consistent with the report by Lu et al. that in Abcd2-deﬁcient
mice, the oxidative stress in adrenal cells was greater than that in
Abcd1-deﬁcient mice [59]. Taken together, ABCD2 appears to have a
central role in the metabolism of mono- and polyunsaturated VLCFA
rather than saturated VLCFA, and may be involved in the regulation
of oxidative stress and the synthesis of DHA.
ABCD2 gene expression is reported to be regulated by nuclear fac-
tors such as the peroxisome proliferator-activated receptor (PPARα),
retinoid X receptor (RXR), thyroid hormone receptor (TRβ) and the
sterol regulatory element (SRE) binding proteins (SREBP1a, SERBP1c
and SREBP2). The SRE located in the ABCD2 promoter overlaps with
a direct repeat separated by 4 nucleotides (DR-4), suggesting cross
talk between SREBPs and liver X receptor α (LXRα) or TRβ, which
are known to dimerize with RXRα [60]. Weinhofer et al. demonstrat-
ed that depression of the cholesterol content results in a decrease in
the C26:0 level, and the expression of the ABCD2 gene is up-
regulated via the activation of the SREBPs [52,61]. In addition, the
ABCD2 promoter contains a functional thyroid hormone response el-
ement (TRE). Recently, it was shown that the ligand-activated thyroid
hormone receptors TRα and TRβ stimulate or derepress, respectively,
the SREBP1-dependent induction of the ABCD2 promoter [60]. These
thyroid hormone receptors bind the SRE/DR-4 motif. Therefore,
novel tissue-speciﬁc ligands for TRα, TRβ or other DR-4 binding fac-
tors that interact with SREBP1, might enhance ABCD2 expression.
4.3. ABCD3
ABCD3 is one of the most abundant peroxisomal membrane pro-
teins, at least in hepatocytes, and has been reported to have a capacity
to transport various fatty acids. Overexpression of ABCD3 stimulates
C16:0 β-oxidation activity in CHO cells, but inhibits C24:0 β-oxidation
activity [16]. In addition, no decrease in the C24:0 β-oxidation activity
was observed by the silencing ABCD3 in ABCD1-knockdown U87 cells
(manuscript in preparation), suggesting that the contribution of
ABCD3 to peroxisomal VLCFA β-oxidation might be negligible. It has
been reported in Abcd3-deﬁcient mice that the bile acid precursors tri-
hydroxycholestanoic acid (THCA) and dihydroxycholestanoic acid
(DHCA), as well as pristanic acid, were accumulated in plasma, and
that the β-oxidation of phytanic and pristanic acid, plant-derived fatty
acids in Abcd3-deﬁcientmouse ﬁbroblasts, was decreased to 50% of con-
trol (Jimenez-Sanchez G et al. Am J Hum Genet 2000, meeting abstract
Nr 282). These results suggest that ABCD3 might function in the trans-
port of LCFA-CoA, THCA-CoA, DHCA-CoA and branched chain acyl-
CoA. This is consistent with the fact that hepatic peroxisomes potently
express ABCD3 and are essential for bile acid synthesis. In the mouse
liver, ABCD3 expression is known to be induced by treatment with
ﬁbrates, such as ciproﬁbrate and fenoﬁbrate, and plasticizers via PPARα.4.4. ABCD4
As mentioned above, we recently reported that ABCD4 is not a
peroxisomal membrane protein but an ER-resident protein, even
though human ABCD4 shares 46% homology with human ABCD1
[19]. It is therefore speculated that ABCD4 functions as a transporter
of certain lipid molecules essential for lipid metabolism in the ER.
However no information on such a function has yet been reported.
5. Role of ABCD1 in CNS and pathogenesis in X-ALD
As judged from the phenotype observed in Abcd1- or Abcd2-
deﬁcient mice as well as X-ALD patients, both ABCD1 and ABCD2
seem to be involved in the maintenance of axonal integrity and/or
myelination. In the CNS, ABCD1 is expressed in endothelial cells, as-
trocytes and microglia, and also in subpopulations of oligodendro-
cytes located in the corpus callosum, internal capsules and anterior
commissure, but not in neurons in the adult mouse or human brain
[62]. In contrast, ABCD2 is expressed in all mouse CNS cells except
for endothelial cells, and the expression pattern mirrors the ABCD1
distribution [63]. Since no disease associated with the mutation of
ABCD2 has been reported, we focus our attention on ABCD1 and X-
ALD in the following subsections.
5.1. VLCFA metabolism in X-ALD
Mutations of the ABCD1 gene [9] result in X-ALD with a birth inci-
dence of 1:17,000 [64]. The affected patients exhibit progressive de-
myelination in the CNS as pathological characteristics [65].
Dysfunction of ABCD1 results in increased levels of saturated (C24:0
and C26:0) and monounsaturated (26:1) VLCFAs in plasma and tis-
sues of patients with X-ALD, and reduced VLCFA β-oxidation in per-
oxisomes [66]. Increased cellular VLCFA-CoAs are thought to be
further elongated by an ER-resided enzyme called elongation of
very long chain fatty acids-1 (ELOVL1), which catalyzes the synthesis
of both saturated (C26:0) and mono-unsaturated VLCFA (C26:1) [51].
The abnormal accumulation of VLCFA is the most likely culprit behind
both the initiation and progression of the disease [67]. Asheuer et al.
found that increase of C26:0 in normal appearing white matter in
child cerebral ALD (CCALD) was higher than adrenomyeloneuropathy
(AMN) [68]. Recently, Jang et al. established induced pluripotent stem
(iPS) cells from X-ALD patients and demonstrated that oligodendro-
cytes differentiated from X-ALD induced-iPS cells displayed an accu-
mulation of C26:0 [69]. Interestingly, C26:0 accumulation was
reported to be much higher in child cerebral ALD (CCALD) oligoden-
drocytes than AMN oligodendrocytes, although the study involved a
single CCALD and a single AMN line.
5.2. The pathogenesis of X-ALD
The mechanism by which the accumulation of VLCFAs in the brain
causes neurodegeneration, especially demyelination, remains ob-
scure. However, the linkage of VLCFA accumulation with the immu-
noresponse is thought to be important. It has been demonstrated
that VLCFA accumulation subsequently leads to a neuroinﬂammatory
response, with the production of proinﬂammatory cytokines by acti-
vated astrocytes and microglial cells together with demyelination
and a loss of oligodendrocytes [70,71]. Hein et al. have shown a direct
toxic effect of VLCFA on primary neurons and glial cells, especially oligo-
dendrocytes, in rat hippocampus culture, via Ca2+ deregulation andmi-
tochondrial dysfunction, probably due to an incorporation of VLCFA into
the mitochondrial inner membrane [72]. The presence of less mature
myelin in both weaning and postweaning rats treated with C26:0
[73], suggests that an increase of VLCFA may lead to myelin instability,
followed by an inﬂammatory or immune-mediated process, and there-
fore contribute, at least in part, to the loss of oligodendrocytes observed
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phospholipids may comprise an antigen recognized by the CD1 path-
way, whichwould be a plausible trigger of inﬂammatory demyelination
[74].
In addition, there is increasing evidence that oxidative stress con-
tributes to the pathogenesis of the cerebral inﬂammatory phenotype
based on in vivo and in vitro studies. Powers et al. found convincing
evidence of oxidative stress and oxidative damage from lipid peroxi-
dation, as well as nitrosylated proteins, in the post-mortem brain tis-
sue of four X-ALD patients with the cerebral inﬂammatory phenotype
[75]. In Abcd1(−/−) mice, oxidative damage in the spinal cord was
observed at as early as 3.5 months of age, more than 1 year before
the neuropathological signs typically appear [76–78]. Furthermore,
incubation of human ﬁbroblasts in the presence of C26:0 resulted in
an increase in the intracellular reactive oxygen species (ROS) level
and the activation of enzymatic antioxidant defenses, indicating a
role for VLCFA in the generation of ROS. In the CNS, a decreased plas-
malogen level due to the dysfunction of ABCD1 might be involved in
the vulnerability to oxidative stress because plasmalogen is known to
possess antioxidant activity [79,80]. Taken together, the dysfunction
of ABCD1 may be correlated with a defective antioxidant response,
and oxidative damage may thus be linked to both the initiation and
the progression of the demyelination.
However, initiation and progression of the X-ALD pathologies can-
not be accounted for only by the accumulation of VLCFA. In addition
to the VLCFA metabolic abnormality, modiﬁer genes and/or environ-
mental factors have been implicated in triggering inﬂammatory de-
myelination [81,82]. Recently, head trauma was reported to initiate
the onset of neurodegeneration [83]. At present, identiﬁcation of the
genetic, epigenetic and environmental factors which trigger this neu-
rodegeneration remains a central issue.
5.3. Role of ABCD1 in glial cells and association with X-ALD
It is plausible that a dysfunction of ABCD1 in glial cells causes the
demyelination. Oligodendrocytes are myelin-producing cells, and as-
trocytes and microglia are known to be important for the support of
axonal growth and myelination. In contrast, the neuron-speciﬁc
peroxisome-knockout mouse model, NEX-Pex5, did not exhibit any
metabolic abnormality or axonal damage, suggesting that ABCD
transporters in neurons are not involved in such neuropathogenesis
[84].
5.3.1. Oligodendrocytes
The dysfunction of ABCD1 in oligodendrocytes unambiguously plays a
crucial role in the disease progression of X-ALD. Is ABCD1 involved in
either axonal integrity or myelination? A study using iPS cells suggested
that ABCD1 is not required for oligodendrocytic maturation, because
ABCD1-deﬁcient iPS cells normally differentiate intomature oligodendro-
cytes [69]. Furthermore, a recent study showed that the lack of functional
peroxisomes in oligodendrocytes resulted in the degradation of myelin-
ated axons, but did not affect oligodendrocyte survival [84,85]. Indeed,
myelination itself is conspicuously normal during brain development in
oligodendrocyte-speciﬁc peroxisome-deﬁcientmice andX-ALDpatients.
It has been thought that the support of axonal survival by oligodendro-
cytes is essential for axonal integrity [86,87]. Therefore, ABCD1 dysfunc-
tion in oligodendrocytes might exert an effect on axonal survival but not
myelination.
5.3.2. Astrocytes
Astrocytes have important roles in both remyelination and the
maintenance of myelin structure [88]. In astrocyte-speciﬁc
peroxisome-deﬁcient mice, the accumulation of VLCFA and decrease
of plasmalogen in the brain were observed, although a deﬁnitive
pathogenetic phenotype was not identiﬁed. Interestingly, in these
mice, the VLCFA accumulation was detected in myelin [84]. Thisresult suggests a metabolic interaction between astrocytes and oligo-
dendrocytes. Astrocytes are known to synthesize various lipids, in-
cluding cholesterol and DHA, and to supply these lipids to other
neural cells for myelination and synaptogenesis [89,90]. Fatty acid
β-oxidation may thus provide acetyl-CoA for de novo fatty acid and
cholesterol synthesis in the brain. It is thus postulated that disruption
of lipid metabolism in ABCD1-deﬁcient astrocytes might affect the oli-
godendrocytic function and further accelerate the demyelination
which occurs in X-ALD.
5.3.3. Microglia
Hematopoietic stem cell transplantation exhibits remarkable efﬁ-
cacy in halting cerebral demyelination in X-ALD, and this effect is
likely due to the functional replacement of brain microglia by bone
marrow-derived cells [91]. This result suggests that the dysfunction
of ABCD1 in microglia contributes to the demyelination in X-ALD.
When X-ALD ﬁbroblasts were co-cultured with N9 cells, a mouse
microglial cell line, the VLCFA level in X-ALD ﬁbroblasts was reduced
by a cell-mediated process [92]. Therefore, ABCD1 in microglia might
be important for the maintenance of VLCFA metabolism in the CNS
and the suppression of the onset or progression of demyelination. In
fact, microglial apoptosis in perilesional white matter represents an
early pathogenic change in CCALD [93].
Taken together, in addition to the dysfunction of ABCD1 in oligo-
dendrocytes, a defect in the metabolic support from astrocytes and
microglia to oligodendrocytes and probably neurons is suggested to
be involved in the demyelination in X-ALD.
6. Peroxisomal ABC transporters in other organisms
A variety of genetic and biochemical studies on ABC transporter
subfamily D from other organisms has been reported. To date, two
ABCD transporters have been described in Saccharomyces cerevisiae
(Pxa1p and Pxa2p), two in Podospora anserina (pABC1 and pABC2),
three in Dictyostelium discoideum (ABCD.1, ABCD.2 and ABCD.3), ﬁve
in Caenorhabditis elegans (pmp1, pmp2, pmp3, pmp4 and pmp5), three
in Trypanosoma brucei (GAT1, GAT2, and GAT3), and two in Arabidopsis
thaliana (CTS/AtABCD1 and AtPMP1/AtABCD2). The following section
describes the current state of knowledge on the ABCD proteins in plants,
protozoa, nematoda and fungi.
6.1. A. thaliana
In A. thaliana, a full-size peroxisomal ABCD transporterwith the char-
acteristics of a fused heterodimer is reported [94–96]. AtABCD1 (also
known as COMATOSE (CTS), Peroxisome defective 3 (PED3), Peroxisomal
ABC transporter 1 (PXA1), Acetate non-utilising 2 (ACN2) and A. thaliana
Peroxisomal Membrane Protein 2 (AtPMP2)) is involved in the transport
of variety of substrates such as fatty acids and hormone precursors into
peroxisomes. Both halves of AtABCD1 have signiﬁcant sequence identity
to human ABCD1. The NBD phylogenetic tree showed that the N- and C-
terminal halves of AtABCD1 cluster with Pxa2p and Pxa1p, respectively
(Fig. 4). In the AtABCD1 mutant, free fatty acids and acyl-CoA, which
are predominantly derived from triacylglycerol, accumulate in seeds
and seedlings [95]. Furthermore, the AtABCD1 mutant under prolonged
dark conditions exhibited an accumulation of free fatty acids in mature
leaves, including palmitic acid, 7,10,13-hexadecatrienoic acid and α-
linolenic acid in mature leaves [97]. These results indicate that AtABCD1
has a role in the transport of acyl-CoA, at least in mature leaves and ger-
minating seeds. This is supported by the result that AtABCD1 exhibits
ATPase activity and recovers from the β-oxidation of saturated or
unsaturated fatty acids with the carbon chain length of C16–C24
when expressed in a yeast pxa1/pxa2-deﬁcient mutant [98].
AtABCD1 is also known to function in the transport into peroxisomes
of 2,4-dichlorophenoxybutyric acid (2,4-DB), indole butyric acid
(IBA) and 12-oxo-phytodienoic acid (OPDA), precursors of jasmonic
ABCD.1
ABCD.3
pmp3
pmp5
ABCD4
Pxa1p GAT2
pABC1
AtABCD2
Pxa2p
GAT1
AtABCD1 
(N-ter)
AtABCD1 
(C-ter)
pmp4
ABCD1
pABC2
ABCD2
pmp1
ABCD3
ABCD.2
pmp2
Fig. 4. Phylogenetic relation of the various ABCD transporters, including the human
(ABCD1, ABCD2, ABCD3 andABCD4), plant (AtABC1 andAtABCD2 inArabidopsis thaliana),
protozoa (GAT1, GAT2, and GAT3 in Trypanosoma brucei), nematoda (pmp1, pmp2, pmp3,
pmp4 and pmp5 in Caenorhabditis elegans), and fungi (Pxa1p and Pxa2p in Saccharomyces
cerevisiae, pABC1 and pABC2 in Podospora anserina, ABCD.1, ABCD.2 and ABCD.3 in
Dictyostelium discoideum). The protein sequences of the nucleotide-binding domains
(NBDs) from various ABCD proteins were assembled and aligned using ClustalW.
Aligned sequences were used to generate matrices of the mean distances between
proteins, and these matrices were used to generate phylogenetic trees according to
the neighbor-joining algorithm.
1393M. Morita, T. Imanaka / Biochimica et Biophysica Acta 1822 (2012) 1387–1396acid [94,99]. These results demonstrate that AtABCD1 supports the β-
oxidation of awide range of fatty acids having a broad range of substrate
speciﬁcity [98], whereas themammalian ABCD transporters havemuch
more restricted substrates.
AtABCD2 (also known as A. thaliana Peroxisomal Membrane Protein
1 (AtPMP1)) encodes a half-size, putative plastid ABC transporter that
has not yet been characterized [100,101]. The NBD phylogenetic tree
indicates that AtABCD2 clusters with human ABCD4 (Fig. 4).
6.2. T. brucei
In T. brucei, three ABC transporters (termed GAT1, 2 and3) have
been identiﬁed in peroxisome-like organelles called glycosomes
[102]. The identity between the Trypanosoma ABCD transporters and
human ABCD transporters is approximately 25% [102]. The NBD phy-
logenetic tree shows that GAT1 clusters with Pxa2p (Fig. 4). GAT1 and
GAT3 are expressed both in the bloodstream and procyclic trypano-
somes, while in contrast GAT2 is mainly or exclusively expressed in
bloodstream-form cells [103]. In mammals, T. brucei live in the blood-
stream and glucose in the blood is converted into pyruvate by the gly-
colytic pathway in their glycosomes for energy intake. Igoillo-Esteve
et al. have demonstrated that the silencing of GAT1 in procyclic cells
cultured in a glucose-free mediumwas lethal [103]. Furthermore, gly-
cosomes puriﬁed from procyclic wild-type cells incorporate oleoyl-
CoA in an ATP-dependent manner, indicating the functional role of
GAT1 in the transport of oleoyl-CoA into the glycosomal lumen. The
functions of GAT2 and GAT3 have not yet been reported.
6.3. C. elegans
In C. elegans, ﬁve ABCD transporters (pmp1–5) have been identi-
ﬁed. The similarity of pmp1, pmp2 and pmp4 to human ABCD2 and
ABCD3 is 55–78% [104]. The NBD phylogenetic tree shows that
pmp1 and pmp2 cluster with human ABCD3, and pmp4 clusters
with human ABCD1 and ABCD2 (Fig. 4). Interestingly, pmp3 and
pmp5 cluster with human ABCD4, which localizes to the ER.The silencing of the pmp1, pmp2 and pmp4 genes caused a sub-
stantial delay in the development of the nematode, indicating that
these ABCD transporters were important for development. The β-
oxidation of polyunsaturated fatty acid and the biosynthesis of plas-
malogen are essential for normal development in C. elegans, suggest-
ing that these ABCD transporters might be involved in the transport
of PUFA and plasmalogen precursor molecules. In C. elegans, peroxi-
somal VLCFA β-oxidation is essential for detoxiﬁcation and biosyn-
thesis of the dauer pheromone, ascaroside, (−)-6-(3,5-dihydroxy-6-
methyltetrahydropyran-2-yloxy) heptanoic acid [105]. Dysfunction
of either of the two peroxisome enzymes, DHS-28 and DFA-22, results
in severe developmental defects, probably because of the massive ac-
cumulation of saturated fatty acids (C20–24) and their acyl-CoAs
(C23–26). It is thus possible that an ABCD transporter such as
pmp1, pmp2 or pmp4 is involved in the transport of VLCFA-CoA
[104]. Further studies will be needed to elucidate the individual func-
tion of these ABCD transporters in C. elegans.6.4. S. cerevisiae, D. discoideum and P. anserina
A search for the yeast homologs of human ABCD1 and ABCD3
resulted in two ABCD1 homologs in S. cerevisiae. They are PXA1
(peroxisomal ABC-transporter 1), also known as PTA1 or PAL1, and
PXA2, also known as PAT1 or YKL741. The NBD phylogenetic tree shows
that Pxa1p and Pxa2p cluster with AtABCD1 (C-terminal) and AtABCD1
(N-terminal), respectively (Fig. 4). Disruption of PXA1 and/or PXA2
resulted in impaired growth of these mutants on oleic acid as a sole
carbon source, and also a reduced ability to oxidize oleate [106].
Furthermore, Verleur et al. showed that Pxa2p is directly responsible for
the ATP-dependent transport of long-chain acyl-CoA across peroxisomal
membranes by using a semi-intact yeast cell system [107]. These results
clearly indicate that Pxa1p/Pxa2p functions as a transporter of acyl-CoA.
Since fatty acid β-oxidation is restricted to peroxisomes in S. cerevisiae, a
PXA1/PXA2-knockout yeast mutant is particularly useful in studying the
substrate speciﬁcity of other ABCD transporters.
In D. discoideum, the dysfunction of the peroxisomal multifunc-
tional enzyme MFE1 led to cAMP-relay and developmental defects,
with an accumulation of excess cyclopropane fatty acids derived
from ingested bacteria [108,109]. There are three ABCD transporters
in Dictyostelium, ABCD.1, ABCD.2 and ABCD.3 [110]. Among them,
the Dictyostelium ABCD.2 protein clusters with the human ABCD3
protein, and Dictyostelium ABCD.1 and ABCD.3 cluster with human
ABCD4 (Fig. 4). Although further studies are needed to elucidate the
function of these transporters, Dictyostelium ABCD.2 might be in-
volved, at least in part, in the transport of cyclopropane fatty acids
into peroxisomes for degradation.
In P. anserina, there are only two genes encoding members of the
ABCD transporter family, pABC1 and pABC2. The sequence similarity
is 45% with human ABCD1, and pABC2 clusters with both human
ABCD1 and ABCD2 (Fig. 4). β-Oxidation of fatty acids occurs in both
mitochondria and peroxisomes, which is different from plants and
other fungi. In addition to the putative function as a fatty acyl-CoA
transporter, pABC1 and pABC2 might have other roles during develop-
mental processes [111]. A defect in pABC1 or pABC2 suppresses the ger-
mination defect in peroxisomal fatty acid β-oxidation deﬁcient
ascospores, suggesting that the absence of pABC1 and/or pABC2 stimu-
lates an unknownmetabolic pathway that results in a compensation for
the germination defects.
Studies of ABCD proteins in other organisms provide clues for un-
derstanding function of mammalian ABCD transporters. C. elegans
possesses a nervous system and has a well known life cycle, which
makes it highly suitable for studying peroxisomal disorders. There-
fore, C. elegans is a valuable model system for investigating defects
in the ABCD transporters. On the other hand, ABCD transporter func-
tion in cellular activities such as germination and sporulation can be
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such systems could lead to the discovery of new functions.
7. Concluding remarks
Further investigation is needed to understand howperoxisomal ABC
proteins work and regulate cellular function. However, in the research
reported over the last few years, considerable progress has been made
on the targeting, assembly and function of the peroxisomal ABC trans-
porters. The expression of human peroxisomal ABC transporters in
yeast lacking PXA1 and PXA2 has clearly demonstrated the substrate
speciﬁcity of human peroxisomal ABC transporters. However, to under-
stand the detailed transport of substrate by the peroxisomal ABC trans-
porters, X-ray crystallographic studies will be required. In addition, to
fully understand the regulation of peroxisomal ABC transporters, prote-
omic approaches which identify interaction partners are also going to
be needed. Characterization of peroxisomal ABC transporters in other
organisms would be helpful in elucidating the role of mammalian
ABCD transporters in cellular function and regulation. Dysfunction of
ABCD1 results in X-ALD and the accumulation of VLCFA seems to be
closely associated with the disease. However, the mechanism by
which the accumulation of VLCFA in the brain causes neurodegenera-
tion remains obscure. Novel approaches may be required to identify
the regulatory networks of the various proteins as well as the micro
RNAs that change in association with the dysfunction of ABCD1 and
the onset of X-ALD in targets cells.
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